sponsored
PatientsVille.com Logo

PatientsVille

Stratter Medical Research Studies

Up-to-date List of Stratter Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Stratter Medical Research Studies

Rank Status Study
1 Recruiting A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
Conditions: Cocaine Dependence;   Opiate Dependence
Interventions: Drug: Atomoxetine, low dose;   Drug: Atomoxetine, high dose;   Drug: Placebo
Outcome Measure: Proportion retained in treatment
2 Recruiting Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia
Conditions: Attention Deficit Hyperactivity Disorder;   Dyslexia
Interventions: Drug: Atomoxetine;   Drug: Placebo
Outcome Measures: To assess the effect of atomoxetine on brain activation pattern during attention & reading tasks in children & adolescents with ADHD & comorbid dyslexia and ADHD alone.;   To assess the correlation between the patterns of brain activation, measured via fMRI, & the clinical findings (ADHDRS & reading scores) in the ADHD alone group & in ADHD with comorbid dyslexia group.;   To assess the effect of atomoxetine on brain activation patterns as patients perform the Stroop attention task, pseudoword rhyming, and semantic-category tasks during fMRI in patients with ADHD alone compared to patients with ADHD & comorbid dyslexia.;   To assess brain activation patterns during fMRI as patients perform the Stroop attention task, pseudoword rhyming, & semantic-category tasks in patients with ADHD alone compared with healthy control subjects.;   To assess brain activation patterns during fMRI as patients perform the Stroop attention task, pseudoword rhyming, & semantic-category tasks in patients with ADHD & comorbid dyslexia compared with healthy control subjects.;   To assess Basic Reading, fluency, comprehension, & spelling skills as measured by Woodcock Johnson III in patients with ADHD alone & ADHD plus comorbid dyslexia.;   To assess phonological processing as measured by the Comprehensive Test of Phonological Processing in patients with ADHD alone & ADHD plus comorbid dyslexia.;   To assess oral reading rate, accuracy, fluency, and comprehension, and overall reading performance as measured by the Gray Oral Reading Tests-4 & Test of Word Reading Efficiency in patients with ADHD alone & ADHD plus comorbid dyslexia.;   To assess working memory & executive functioning as measured by WMTB-C & Brown Attention-Deficit Disorder Scale-Adolescent Version (BADD-A), respectively in patients with ADHD alone & ADHD plus comorbid dyslexia.;   To evaluate maintenance of benefit after discontinuation of treatment with atomoxetine in patients who were previously assigned to atomoxetine during the acute treatment period. These patients will be re-randomized to atomoxetine or placebo.;   To assess safety & tolerability of atomoxetine in the ADHD alone group, ADHD with comorbid dyslexia group, & dyslexia alone group as assessed by laboratory, vitals, ECG measures, & adverse events collection.
3 Unknown  Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD
Conditions: Fetal Alcohol Syndrome;   Attention Deficit Disorder With Hyperactivity (ADHD);   Attention Deficit Disorder (ADD)
Interventions: Drug: Strattera;   Drug: Placebo
Outcome Measures: ADHD Rating Scale - IV;   Determine if atomoxetine is safe and well tolerated by children with FAS.;   Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo.;   Determine if atomoxetine improves behaviors in the mornings and evenings.;   Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine.;   Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine.;   Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI)
4 Recruiting Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Condition: Methamphetamine Dependence
Interventions: Drug: Atomoxetine;   Drug: placebo
Outcome Measure: Time till relapse
5 Recruiting Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers
Condition: Nicotine Dependence
Intervention: Drug: Atomoxetine
Outcome Measures: Nicotine Effects Questionnaire;   Center for Epidemiologic Studies Depression (CES-D) scale;   Positive and Negative Affect Schedule (PANAS );   The Profile of Mood States (POMS);   Symptom Checklist Form (SCF);   Nicotine Withdrawal Symptom Checklist (NWSC)
6 Unknown  Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Conditions: Fetal Alcohol Syndrome;   Attention Deficit Disorder (ADD);   Attention Deficit Disorder With Hyperactivity (ADHD)
Intervention: Drug: atomoxetine hydrochloride
Outcome Measures: Determine if atomoxetine is safe and well tolerated by children with FASD.;   Determine if there are any differences in the adverse effects profile of children with FASD compared to the overall profile for atomoxetine.;   Determine if changes in behavior seen with short-term (eight weeks) treatment of children are maintained over a twelve month period.;   Compare growth while on atomoxetine with growth before entry into study.
7 Recruiting Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
Conditions: Parkinson's Disease;   Cognitive Impairment
Interventions: Drug: Atomoxetine;   Drug: Placebo
Outcome Measures: Neuropsychological Testing Battery;   Safety measures
8 Recruiting Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
Condition: Autism
Interventions: Drug: Atomoxetine;   Drug: Placebo
Outcome Measures: ADHD symptoms;   Irritability and anxiety;   Core autistic symptoms;   Quality of life
9 Recruiting Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Condition: Type 1 Diabetes
Interventions: Drug: Atomoxetine;   Drug: Placebo
Outcome Measure: Change in level of catecholamines in blood from baseline
10 Recruiting Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Conditions: Attention Deficit Hyperactivity Disorder;   ADHD
Interventions: Other: fMRI scans;   Drug: Atomoxetine arm;   Drug: Methylphenidate arm
Outcome Measures: Brain Activation;   Go-Nogo;   ADHD-RS
11 Recruiting Effects of Atomoxetine in Mild Cognitive Impairment
Condition: Mild Cognitive Impairment
Interventions: Drug: Atomoxetine;   Drug: Placebo
Outcome Measures: Cerebrospinal fluid biomarkers of inflammation;   Biomarkers of noradrenergic function;   Number of Adverse Events;   Cerebrospinal fluid biomarkers of neurodegeneration;   Imaging biomarkers of neurodegeneration;   Cognitive measures;   Behavioral symptoms
12 Unknown  Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: atomoxetine
Outcome Measures: Improvement of ADHD symptoms as rated by ADHD Rating Scale: IV (Investigator Rated);   Improvement of ADHD symptoms as rated by ADHD Rating Scale: IV (Parent Rated);   Improvement of ADHD symptoms as rated by ADHD Rating Scale: IV (Teacher Rated);   Improvement of behaviors as rated by IOWA Conners Rating Scale (Parent Rated);   Improvement of behaviors as rated by IOWA Conners Rating Scale (Teacher Rated);   Improvement in Clinical Global Impression: Severity;   Side effect
13 Recruiting Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
Conditions: Opiate Dependence;   Stimulant Dependence
Intervention: Drug: Atomoxetine
Outcome Measures: ATS (Amphetamine-type stimulant) Use;   Retention;   HIV Risks;   Functional status
14 Not yet recruiting Progesterone and Atomoxetine for Cocaine Cessation
Conditions: Cocaine Addiction;   Smoking Addiction
Interventions: Drug: Progesterone;   Drug: Atomoxetine
Outcome Measures: Cocaine Cessation;   Impulsivity
15 Unknown  The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder
Condition: Attention Deficit Hyperactivity Disorder
Intervention:
Outcome Measure:
16 Unknown  Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD);   Insomnia
Intervention: Drug: atomoxetine
Outcome Measures: mean sleep onset latency;   parent and child-reported evening settling difficulties;   night wakings, sleep duration, and sleep efficiency;   daytime sleepiness;   ADHD symptom improvement;   executive functions and functional outcomes/quality of life
17 Recruiting Treatment of Orthostatic Intolerance
Conditions: Tachycardia;   Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide;   Drug: Atomoxetine;   Other: NO Drug;   Drug: Clonidine;   Drug: Entacapone;   Drug: Entacapone & Propranolol;   Drug: Atomoxetine & Propranolol;   Drug: Indomethacin;   Drug: Mecamylamine;   Drug: Isosorbide Dinitrate;   Dietary Supplement: Melatonin;   Drug: Midodrine;   Drug: Modafinil;   Drug: Octreotide;   Radiation: Placebo;   Drug: Propranolol;   Drug: Modafinil & Propranolol;   Drug: Sertraline;   Procedure: IV Saline;   Other: Drinking Water;   Device: Breathing Device;   Drug: memantine;   Device: Abdominal binder
Outcome Measures: Increase in heart rate with standing;   Sitting heart rate;   Standing heart rate;   Blood pressure;   Decrease in blood pressure with standing;   Orthostatic symptoms score
18 Recruiting Cognitive Decline in Non-demented PD
Condition: Parkinson's Disease
Interventions: Drug: Strattera;   Drug: Exelon;   Other: Placebo
Outcome Measures: Attention network effects;   Quality of life;   Stroop Color Word Test;   Fatigue;   Depression;   Daytime sleepiness
19 Unknown  Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Atomoxetine;   Drug: Methylphenidate
Outcome Measures: ADHD-Rating Scale (ADHD RS)- IV- Parent Version;   Clinical Global Impressions (CGI)- Severity, Overall, Improvement;   Conners Parent Rating Scale- Short Form;   Atomoxetine-Stimulant Side Effects Ratings Scale;   Weiss Functional Impairment Scale;   Conners-Wells Adolescent Self Report;   Conners Teacher Rating Scale- Short;   Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL);   Psychiatric History and Mental Status Examination;   Child Behavior Checklist (CBCL);   Social Skills Rating Scale (SSRS)- Parent Version;   Social Skills Rating Scale (SSRS)- Teacher Version;   Child Conflict Index (CCI);   Wechsler Intelligence Scale for Children - 4th Edition (WISC-IV);   Wechsler Individual Achievement Test II Abbreviated (WIAT II A);   Continuous Performance Test (CPT);   Permanent Mathematics Product Test (PERMP);   Children's Sleep Questionnaire;   Actigraphy;   Sleep logs;   Hyperactivity, Attention, and Learning Problems (HALP) Medical and Developmental History Questionnaire;   Vital signs;   Open Ended Adverse Event Questioning;   Modified Yale Global Tic Severity Scale;   Assessment of Affective Range (AAR);   Treatment Preference Survey;   HALP Rebound Effects Questionnaire
20 Not yet recruiting ADHD Medication and Predictors of Treatment Outcome
Condition: Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions: Drug: methylphenidate medication;   Drug: atomoxetine medication;   Drug: lisdexamphetamine medication
Outcome Measures: change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale);   change in P-SEC (Pediatric Side Effects Checklist);   change in CGI-S (Clinical Global Impression- of Severity);   change in C-GAS (Children´s global assessment scale);   change in SNAP-IV Teacher and Parent rating scale;   change in Spence Children's Anxiety Scale (SCAS);   change in heart rate;   change in systolic blood pressure;   change in diastolic blood pressure;   change in weight z-score;   change in height z-score

These studies may lead to new treatments and are adding insight into Stratter etiology and treatment.

A major focus of Stratter research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Stratter